Open Call MSCA-IF-2018: Individual Fellowships

European CommissionThe goal of the Individual Fellowships is to enhance the creative and innovative potential of experienced researchers, wishing to diversify their individual competence in terms of skill acquisition through advanced training, international and intersectoral mobility. Individual Fellowships provide opportunities to researchers of any nationality to acquire and transfer new knowledge and to work on research and innovation in Europe (EU Member States and Horizon 2020 Associated Countries) and beyond. The scheme particularly supports the return and (re)integration of European researchers from outside Europe and those who have previously worked here, as well as researchers displaced by conflict outside the EU and Horizon 2020 Associated Countries. It also promotes the career restart of individual researchers who show great potential.

Support is foreseen for individual, trans-national fellowships awarded to the best or most promising researchers of any nationality, for employment in EU Member States or Horizon 2020 Associated Countries. It is based on an application made jointly by the researcher and the beneficiary in the academic or non-academic sectors.

Only one proposal per individual researcher per call will be evaluated.

Fellowships take the form of European Fellowships or Global Fellowships. European Fellowships are held in EU Member States or Horizon 2020 Associated Countries and are open to researchers either coming to Europe from any country in the world or moving within Europe. The researcher must comply with the rules of mobility in the country where the European Fellowship is held.

Direct return to and long-term reintegration of researchers in Europe, including in their country of origin, is supported via a separate multi-disciplinary reintegration panel of the European Fellowships. For the reintegration panel, there must be direct mobility to the country of the beneficiary in Europe from a third country (compulsory national service and/or short stays such as holidays are not taken into account).

Support to individuals to resume research in Europe after a career break, e.g. after parental leave or due to recent migration, is ensured via a separate multi-disciplinary career restart panel of the European Fellowships. To qualify for the career restart panel, researchers must not have been active in research for a continuous period of at least 12 months within the 18 months immediately prior to the deadline for submission.

Researchers seeking to work on research and innovation projects in an organisation from the non-academic sector will be supported via a separate multi-disciplinary society and enterprise panel of the European Fellowships. The objective of this panel is to facilitate career moves between the academic and non-academic sectors, to stimulate innovation, and to open attractive career opportunities for researchers outside academia.

Deadline: 12 September 2018 17:00:00

Deadline Model: single-stage

Type of action:

  • MSCA-IF-GF Global Fellowships
  • MSCA-IF-EF-ST Standard European Fellowships
  • MSCA-IF-EF-SE Society and Enterprise panel
  • MSCA-IF-EF-RI Reintegration panel
  • MSCA-IF-EF-CAR Career Restart panel

For topic conditions, documents and submission service, please visit:
https://ec.europa.eu/research/participants/portal/desktop/en/opportunities/h2020/topics/msca-if-2018.html

PS: Find your partners or consortia preparing a project proposal
If you are working on Horizon 2020 research project proposals and you would be interested in a SME partner from Germany, please contact us, we are happy to share our experience, expertise and knowledge. If you need help to identify a potential partner with particular competences, facilities or experience, please join and explore our project, (HEALTH IT) SPACE, at www.healthitspace.eu.

Most Popular Now

New AI Diagnostic can Predict COVID-19 w…

Researchers at King's College London, Massachusetts General Hospital and health science company ZOE have developed an artificial intelligence diagnostic that can predict whether someone is likely to have COVID-19 based...

Elsevier Adds to its Extensive Free Reso…

Elsevier, a global leader in information analytics specializing in science and health, is offering free access to a unique set of biomedical research tools and content to help researchers and...

Philips Launches HealthSuite Clinical Tr…

Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, announced Clinical Trial Accelerator on Philips HealthSuite. This new tailored set of capabilities allows life science organizations to...

An EU Approach for Efficient Contact Tra…

EU Members States, supported by the Commission, have developed an EU toolbox for the use of mobile applications for contact tracing and warning in response to the coronavirus pandemic. This...

Biomax Provides AI-Based Semantic Search…

The bioinformatics company Biomax, headquartered in Planegg, Germany, makesitssemantic search platform AILANI available free of charge to research institutes around the world in order to support the rapid and successful...

COVID-19 and Health Tech: Building on th…

Highland Marketing's advisory board met to discuss the health tech response to the coronavirus outbreak. In many areas, this has been hugely impressive: but there are gaps, and there will...

InsurTech Hub Munich and dmac/Digital He…

InsurTech Hub Munich (ITHM) and dmac - Medical Valley Digital Health Application Center part of the Digital Health Hub Nuremberg/Erlangen announce a new cross-industry accelerator for the second half of...

Telemedicine Transforms Response to COVI…

A rapid increase in "virtual" visits during the COVID-19 pandemic could transform the way physicians provide care in the United States going forward, according to a new study led by...

Viveo Health Offers Free Telemedicine So…

Viveo Health, a global e-Health innovator, is making its 'Virtual Office for Doctors' platform free of charge to doctors and other medical professionals worldwide in light of the surge in...

Supercomputer Simulations Present Potent…

Several drugs approved for treating hepatitis C viral infection were identified as potential candidates against COVID-19, a new disease caused by the SARS-CoV-2 coronavirus. This is the result of research...

The Dedalus Group, Participated by Ardia…

The Dedalus Group, a leading European company, and one of the worldwide main ones, active in clinical healthcare information systems to support clinical professionals and organizations in order to improve...

The COVID-19 pandemic reveals the potent…

Two new articles provide insights on the use of telehealth or virtual care in the age of COVID-19 and beyond, pointing to its value to not only prevent contagious diseases...